Furthermore, as PIK3CD and AKT3 genes are actively involved in cell proliferation, it is likely that the acquisition of these specific point mutations in MDS not responding to therapy could give a proliferative advantage to mutated cells. This evidence concerns the gene PIK3CD and myelodysplastic syndrome.